Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
18 11 2022
Historique:
entrez: 16 11 2022
pubmed: 17 11 2022
medline: 19 11 2022
Statut: ppublish

Résumé

6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist that suppresses cancer cell metabolism but concurrently enhances the metabolic fitness of tumor CD8

Identifiants

pubmed: 36383674
doi: 10.1126/sciadv.abq5925
pmc: PMC9668306
doi:

Substances chimiques

Prodrugs 0
Diazooxonorleucine 03J0H273KZ
Glutamine 0RH81L854J
Enzyme Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabq5925

Subventions

Organisme : NCI NIH HHS
ID : T32 CA060441
Pays : United States

Références

Cancer Treat Rep. 1982 May;66(5):1215-7
pubmed: 7083223
Pharmacol Rev. 2011 Sep;63(3):750-71
pubmed: 21737530
Int J Oncol. 2013 Feb;42(2):373-83
pubmed: 23291656
Cancer. 2012 Jun 1;118(11):2986-96
pubmed: 22006342
Nat Rev Drug Discov. 2018 Aug;17(8):559-587
pubmed: 29700501
Am J Clin Oncol. 1983 Jun;6(3):325-6
pubmed: 6846250
Lancet. 2015 Jun 27;385(9987):2559-60
pubmed: 25890672
Clin Cancer Res. 2003 Oct 15;9(13):4983-91
pubmed: 14581373
Cancer Res. 1979 Aug;39(8):3220-4
pubmed: 572261
Anticancer Drugs. 1996 Jun;7(4):437-60
pubmed: 8826613
Oncogene. 2010 Jan 21;29(3):313-24
pubmed: 19881548
Molecules. 2020 Feb 17;25(4):
pubmed: 32079289
Theranostics. 2018 Feb 16;8(7):2018-2030
pubmed: 29556370
Proc Natl Acad Sci U S A. 1980 Apr;77(4):2224-8
pubmed: 6246527
Cancer Res. 1966 Feb;26(2):282-6
pubmed: 4285554
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Curr Drug Metab. 2021;22(9):735-745
pubmed: 34488583
Cancer Treat Rep. 1982 Aug;66(8):1665-6
pubmed: 6286122
Biochem Biophys Res Commun. 2014 Jan 3;443(1):32-6
pubmed: 24269238
Science. 1987 Mar 20;235(4795):1492-5
pubmed: 3103217
Invest New Drugs. 1985;3(4):369-74
pubmed: 4086244
Pharmacol Ther. 1990;46(2):243-71
pubmed: 2108451
Expert Opin Investig Drugs. 2007 Jul;16(7):1037-58
pubmed: 17594188
Mol Cancer Ther. 2020 Feb;19(2):397-408
pubmed: 31594823
J Pharm Sci. 2006 Jun;95(6):1177-95
pubmed: 16639719
Curr Protoc Bioinformatics. 2016 Sep 07;55:14.10.1-14.10.91
pubmed: 27603023
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
pubmed: 18032601
Cancer Res. 1982 Jan;42(1):207-18
pubmed: 7032691
Cell Cycle. 2004 Dec;3(12):1516-619
pubmed: 15539953
Theranostics. 2012;2(2):156-78
pubmed: 22400063
J Med Chem. 2019 Apr 11;62(7):3524-3538
pubmed: 30892035
Cancer Chemother Pharmacol. 1988;21(1):78-84
pubmed: 3342470
J Med Chem. 2016 Sep 22;59(18):8621-33
pubmed: 27560860
J Control Release. 2016 Oct 28;240:67-76
pubmed: 26514292
J Clin Invest. 2020 Jul 1;130(7):3865-3884
pubmed: 32324593
Clin Pharmacokinet. 2001;40(2):85-104
pubmed: 11286326
Biochem Pharmacol. 1976 Aug 15;25(16):1851-8
pubmed: 9091
J Clin Invest. 2022 Jan 4;132(1):
pubmed: 34981784
Clin Cancer Res. 2004 Feb 15;10(4):1446-53
pubmed: 14977848
Expert Rev Anticancer Ther. 2019 Jun;19(6):483-502
pubmed: 31055990
Biomol Ther (Seoul). 2018 Jan 1;26(1):19-28
pubmed: 29212303
Cell Metab. 2012 Jan 4;15(1):110-21
pubmed: 22225880
Biochem Med Metab Biol. 1987 Oct;38(2):127-33
pubmed: 2823852
J Clin Invest. 2013 Sep;123(9):3678-84
pubmed: 23999442
Chem Res Toxicol. 2011 Nov 21;24(11):1891-8
pubmed: 21875074
Eur J Cancer Clin Oncol. 1985 Mar;21(3):307-16
pubmed: 3891358
Nat Commun. 2013;4:2735
pubmed: 24193185
J Med Chem. 2017 Aug 24;60(16):7186-7198
pubmed: 28759224
Bioconjug Chem. 2001 Nov-Dec;12(6):1074-80
pubmed: 11716702
Cancer Res. 1957 Nov;17(10):1033-9
pubmed: 13489704
Biochem Pharmacol. 2005 Nov 25;70(11):1673-84
pubmed: 16213467
Trends Biochem Sci. 2010 Aug;35(8):427-33
pubmed: 20570523
Int J Cancer. 2010 Nov 15;127(10):2478-85
pubmed: 20473919
Cancer. 1957 Nov-Dec;10(6):1138-50
pubmed: 13489662
Biochem Biophys Res Commun. 2013 Aug 23;438(2):243-8
pubmed: 23850693
Nat Rev Cancer. 2010 Apr;10(4):267-77
pubmed: 20300106
Science. 2019 Nov 22;366(6468):1013-1021
pubmed: 31699883
J Med Chem. 2018 May 10;61(9):3918-3929
pubmed: 29648826
Invest New Drugs. 1990 Feb;8(1):113-9
pubmed: 2188926
J Clin Invest. 2020 Jan 2;130(1):451-465
pubmed: 31613799
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76
pubmed: 25197329
J Alzheimers Dis. 2020;77(1):437-447
pubmed: 32675407
Adv Drug Deliv Rev. 2011 Jul 18;63(8):659-70
pubmed: 21333700
Cancer Treat Rep. 1979 Jun;63(6):1033-8
pubmed: 380801
Mol Cancer Ther. 2018 Sep;17(9):1824-1832
pubmed: 30181331
Methods Enzymol. 1977;46:414-27
pubmed: 909432
Clin Cancer Res. 2001 Aug;7(8):2182-94
pubmed: 11489791
J Cheminform. 2010 Oct 18;2(1):9
pubmed: 20955607
Am J Clin Oncol. 1982 Oct;5(5):541-3
pubmed: 7180833
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7705-10
pubmed: 22538822
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1031-6
pubmed: 7296548
J Biol Chem. 1957 Mar;225(1):163-76
pubmed: 13416227
Cancer Chemother Rep. 1962 May;18:83-95
pubmed: 13918321

Auteurs

Rana Rais (R)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Kathryn M Lemberg (KM)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Lukáš Tenora (L)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 16000, Czech Republic.

Matthew L Arwood (ML)

The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

Arindom Pal (A)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Jesse Alt (J)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Ying Wu (Y)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Jenny Lam (J)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Joanna Marie H Aguilar (JMH)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Liang Zhao (L)

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

Diane E Peters (DE)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Carolyn Tallon (C)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Rajeev Pandey (R)

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Ajit G Thomas (AG)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Ranjeet P Dash (RP)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Tanguy Seiwert (T)

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Pavel Majer (P)

Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 16000, Czech Republic.

Robert D Leone (RD)

Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

Jonathan D Powell (JD)

Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

Barbara S Slusher (BS)

Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH